MedTrace Logo

Oral Tranexamic Acid and Laser for Treatment of Melasma

NCT03686787 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-09-27

No results posted yet for this study

Summary

Tranexamic acid and 1927 diode laser non-ablative fractionated laser for the treatment of Melasma.

Conditions

  • Melasma

Interventions

DRUG

Tranexamic Acid

A split face study of oral tranexamic acid in combination with laser treatment

Sponsors & Collaborators

  • Dermatology & Laser Surgery Center, Houston, TX

    collaborator UNKNOWN

  • Laser and Skin Surgery Center of New York

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-07-31
Completion
2019-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03686787 on ClinicalTrials.gov